ERASCA INC (ERAS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ERAS • US29479A1088

10.61 USD
+0.1 (+0.95%)
At close: Feb 2, 2026
10.7999 USD
+0.19 (+1.79%)
After Hours: 2/2/2026, 8:01:45 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ERAS. ERAS was compared to 524 industry peers in the Biotechnology industry. While ERAS has a great health rating, there are worries on its profitability. ERAS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ERAS had negative earnings in the past year.
  • ERAS had a negative operating cash flow in the past year.
  • ERAS had negative earnings in each of the past 5 years.
  • ERAS had a negative operating cash flow in each of the past 5 years.
ERAS Yearly Net Income VS EBIT VS OCF VS FCFERAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • ERAS has a better Return On Assets (-30.37%) than 66.79% of its industry peers.
  • ERAS's Return On Equity of -36.70% is fine compared to the rest of the industry. ERAS outperforms 72.52% of its industry peers.
Industry RankSector Rank
ROA -30.37%
ROE -36.7%
ROIC N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ERAS Yearly ROA, ROE, ROICERAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ERAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERAS Yearly Profit, Operating, Gross MarginsERAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ERAS has been increased compared to 1 year ago.
  • ERAS has more shares outstanding than it did 5 years ago.
  • ERAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ERAS Yearly Shares OutstandingERAS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ERAS Yearly Total Debt VS Total AssetsERAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • ERAS has an Altman-Z score of 21.52. This indicates that ERAS is financially healthy and has little risk of bankruptcy at the moment.
  • ERAS's Altman-Z score of 21.52 is amongst the best of the industry. ERAS outperforms 90.08% of its industry peers.
  • There is no outstanding debt for ERAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.52
ROIC/WACCN/A
WACCN/A
ERAS Yearly LT Debt VS Equity VS FCFERAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 10.45 indicates that ERAS has no problem at all paying its short term obligations.
  • ERAS's Current ratio of 10.45 is amongst the best of the industry. ERAS outperforms 82.63% of its industry peers.
  • ERAS has a Quick Ratio of 10.45. This indicates that ERAS is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ERAS (10.45) is better than 82.63% of its industry peers.
Industry RankSector Rank
Current Ratio 10.45
Quick Ratio 10.45
ERAS Yearly Current Assets VS Current LiabilitesERAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

  • ERAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.78%, which is quite impressive.
EPS 1Y (TTM)45.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ERAS will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.77% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.89%
EPS Next 2Y16.05%
EPS Next 3Y9.39%
EPS Next 5Y8.77%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERAS Yearly Revenue VS EstimatesERAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
ERAS Yearly EPS VS EstimatesERAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • ERAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ERAS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERAS Price Earnings VS Forward Price EarningsERAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERAS Per share dataERAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.05%
EPS Next 3Y9.39%

More info and screens

0

5. Dividend

5.1 Amount

  • ERAS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ERASCA INC

NASDAQ:ERAS (2/2/2026, 8:01:45 PM)

After market: 10.7999 +0.19 (+1.79%)

10.61

+0.1 (+0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-18
Inst Owners73.03%
Inst Owner Change-0.64%
Ins Owners7.33%
Ins Owner Change0%
Market Cap3.01B
Revenue(TTM)N/A
Net Income(TTM)-127.69M
Analysts81.33
Price Target6.53 (-38.45%)
Short Float %8.99%
Short Ratio4.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.66%
Min EPS beat(2)-6.95%
Max EPS beat(2)-4.37%
EPS beat(4)2
Avg EPS beat(4)4.03%
Min EPS beat(4)-6.95%
Max EPS beat(4)14.41%
EPS beat(8)4
Avg EPS beat(8)-0.32%
EPS beat(12)7
Avg EPS beat(12)-14.37%
EPS beat(16)10
Avg EPS beat(16)-8.25%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)30.91%
PT rev (3m)37.14%
EPS NQ rev (1m)1.4%
EPS NQ rev (3m)1.65%
EPS NY rev (1m)0.09%
EPS NY rev (3m)-1.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.65
P/tB 8.65
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS1.23
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.37%
ROE -36.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.72%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.45
Quick Ratio 10.45
Altman-Z 21.52
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)200.09%
Cap/Depr(5y)425.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y38.89%
EPS Next 2Y16.05%
EPS Next 3Y9.39%
EPS Next 5Y8.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.41%
EBIT Next 3Y1.82%
EBIT Next 5Y-2.35%
FCF growth 1Y6.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.37%
OCF growth 3YN/A
OCF growth 5YN/A

ERASCA INC / ERAS FAQ

Can you provide the ChartMill fundamental rating for ERASCA INC?

ChartMill assigns a fundamental rating of 3 / 10 to ERAS.


What is the valuation status of ERASCA INC (ERAS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ERASCA INC (ERAS). This can be considered as Overvalued.


What is the profitability of ERAS stock?

ERASCA INC (ERAS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ERASCA INC?

The Earnings per Share (EPS) of ERASCA INC (ERAS) is expected to grow by 38.89% in the next year.